Werewolf Therapeutics, Inc. (HOWL): Price and Financial Metrics
HOWL Price/Volume Stats
| Current price | $5.90 | 52-week high | $8.19 |
| Prev. close | $5.87 | 52-week low | $1.57 |
| Day low | $5.62 | Volume | 120,900 |
| Day high | $5.98 | Avg. volume | 244,616 |
| 50-day MA | $6.26 | Dividend yield | N/A |
| 200-day MA | $3.84 | Market Cap | 255.75M |
HOWL Stock Price Chart Interactive Chart >
Werewolf Therapeutics, Inc. (HOWL) Company Bio
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It offers PREDATOR, a platform of protein engineering technology to design and engineer the future of immuno-oncology biotherapeutics for patients. The company's lead product candidates include WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. It also develops WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
Latest HOWL News From Around the Web
Below are the latest news stories about WEREWOLF THERAPEUTICS INC that investors may wish to consider to help them evaluate HOWL as an investment opportunity.
Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Stock Catapults 26% Though Its Price And Business Still Lag The IndustryWerewolf Therapeutics, Inc. ( NASDAQ:HOWL ) shareholders would be excited to see that the share price has had a great... |
Institutions profited after Werewolf Therapeutics, Inc.'s (NASDAQ:HOWL) market cap rose US$14m last week but private equity firms profited the mostKey Insights Werewolf Therapeutics' significant private equity firms ownership suggests that the key decisions are... |
Werewolf Therapeutics to Present at the Evercore ISI HealthCONx ConferenceWATERTOWN, Mass., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf, and Randi Isaacs, M.D., Chief Medical Officer of Werewolf, will participate in a fireside c |
Werewolf Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update– Preliminary data from the WTX-124 monotherapy dose-escalation arm of the ongoing Phase 1/1b clinical trial provide compelling early evidence of dose-dependent anti-tumor and biomarker activity – – Safety data indicate WTX-124 is generally well tolerated through cohort 4 (12 mg), with a wide therapeutic index supportive of continued dose escalation – – Additional interim WTX-124 monotherapy data and recommended dose for expansion expected in the first half of 2024 – – Announcing the addition of |
CVNA Stock Alert: What Analysts Are Saying After Carvana’s Q3 EarningsCarvana stock is on the move as analysts weigh in on CVNA shares following the release of the company's latest earnings report. |
HOWL Price Returns
| 1-mo | 0.85% |
| 3-mo | 39.48% |
| 6-mo | 231.46% |
| 1-year | 150.00% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 52.85% |
| 2023 | 88.29% |
| 2022 | -82.79% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...